Phase I study of bevacizumab, sorafenib, and low-dose cyclophosphamide (CYC) in children and young adults with refractory solid tumors.

被引：2
|
作者：
Santana, V. M. [1 ]
Baker, S. D. [1 ]
McCarville, B. [1 ]
Stewart, C. F. [1 ]
Wu, J. [1 ]
Billups, C. [1 ]
Spunt, S. L. [1 ]
Furman, W. L. [1 ]
McGregor, L. M. [1 ]
Hu, S. [1 ]
Panetta, J. C. [1 ]
Reddick, W. E. [1 ]
Davidoff, A. [1 ]
Leung, W. H. [1 ]
Navid, F. [1 ]
机构：
[1] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.9500
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9500
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: A pediatric oncology group study
    Aquino, VM
    Weitman, SD
    Winick, NJ
    Blaney, S
    Furman, WL
    Kepner, JL
    Bonate, P
    Krailo, M
    Qu, WC
    Bernstein, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) : 1413 - 1419
  • [32] A phase I study of temsirolimus plus erlotinib in patients with refractory solid tumors.
    Wang-Gillam, Andrea
    Tan, Benjamin R.
    Waqar, Saiama Naheed
    Suresh, Rama
    Morgensztern, Daniel
    Van Tine, Brian Andrew
    Nieman, Rebecca
    Govindan, Ramaswamy
    Lockhart, Albert C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] Phase I dose escalation and pharmacokinetics clinical trial of mitoxantrone hydrochloride liposome in children with relapsed and refractory solid tumors.
    Huang, Junting
    Ji, Mingqing
    Li, Hui
    Wu, Yanpeng
    Cai, Ruiqing
    Wang, Juan
    Lu, Suying
    Zhu, Jia
    Sun, Feifei
    Zhen, Zijun
    Zhang, Yizhuo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Phase II trial of dose-escalated sorafenib in advanced solid tumors.
    Semrad, T. J.
    Eddings, C.
    Pan, C.
    Lau, D.
    Gandara, D. R.
    Beckett, L.
    Lara, P., Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors.
    Wood, Paul James
    Strong, Robyn
    McArthur, Grant A.
    Michael, Michael
    Algar, Elizabeth
    Muscat, Andrea
    Rigby, Lin
    Ashley, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] Phase I study of the combination of BKM120 and bevacizumab in patients with relapsed/refractory glioblastoma multiforme (GBM) or other refractory solid tumors.
    Shih, Kent C.
    Acs, Peter
    Burris, Howard A.
    Hart, Lowell L.
    Kosloff, Rebecca A.
    Lamar, Ruth E.
    Hainsworth, John D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] Phase IB dose escalation study of bortezomib and sunitinib in patients with refractory solid tumors.
    Kauh, J. S.
    Harvey, R. D.
    Lawson, D. H.
    Owonikoko, T. K.
    Tighiouart, M.
    Ramalingam, S. S.
    Shin, D. M.
    Lewis, C. M.
    El-Rayes, B. F.
    Khuri, F. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Phase I and pharmacokinetic study of low-dose, three-times daily oral etoposide in patients with refractory solid tumors
    Schwartsmann, G
    Di Leone, L
    Caldas, APF
    Campos, O
    Viegas, MAV
    Cancela, AI
    Sander, E
    Ferreira, F
    Schunemann, H
    Mans, DRA
    17TH INTERNATIONAL CANCER CONGRESS, VOL 1 AND 2, 1998, : 1481 - 1482
  • [39] Phase I and pharmacokinetic study of low-dose, three-times daily oral etoposide in patients with refractory solid tumors
    Schwartsmann, G
    Di Leone, L
    Caldas, APF
    Campos, O
    Cancela, AI
    Viegas, MAV
    Mans, DRA
    ANNALS OF ONCOLOGY, 1998, 9 : 138 - 138
  • [40] Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas
    Aspeslagh, Sandrine
    Stein, Mark
    Bahleda, Rastilav
    Hollebecque, Antoine
    Salles, Gilles
    Gyan, Emmanuel
    Fudio, Salvador
    Extremera, Sonia
    Alfaro, Vicente
    Soto-Matos, Arturo
    Soria, Jean-Charles
    ANTI-CANCER DRUGS, 2017, 28 (03) : 341 - 349
12345